» Articles » PMID: 25927351

Pre-emptive Steroids for a Severe Oedematous Buruli Ulcer Lesion: a Case Report

Overview
Journal J Med Case Rep
Publisher Biomed Central
Specialty General Medicine
Date 2015 May 1
PMID 25927351
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Severe oedematous forms of Buruli ulcer (BU) often result in extensive tissue destruction, even with the institution of appropriate antibiotic treatment, leading to reconstructive surgery and long-term disability. We report a case of a patient with severe oedematous BU, which describes for the first time the pre-emptive use of prednisolone therapy commenced at the time of antibiotic initiation aimed at limiting the ongoing tissue destruction and its secondary sequelae.

Case Presentation: A 91-year-old Australian-born Caucasian woman presented with a WHO category 3 oedematous BU lesion on the anterior aspect of her right ankle that she had first noticed three weeks earlier. Treatment was commenced with an antibiotic combination of rifampicin and ciprofloxacin. At the same time, pre-emptive prednisolone was commenced (a dose of 0.5mg/kg daily). Treatment resulted in rapid and significant reduction in the size of the induration associated with the lesion, and no significant increase in the size of the skin ulceration. Antibiotics were continued for 56 days and prednisolone therapy ceased 130 days after antibiotics commenced. No surgery was required. The wound healed completely after 10 months and there was no long-term limitation of movement at the ankle joint.

Conclusions: Pre-emptive corticosteroid therapy may prevent further progressive tissue necrosis and the need for secondary reconstructive surgery that commonly occurs during the antibiotic treatment of severe odematous forms of BU.

Citing Articles

A human model of Buruli ulcer: Provisional protocol for a controlled human infection study.

Muhi S, Marshall J, OBrien D, Johnson P, Ross G, Ramakrishnan A Wellcome Open Res. 2024; 9:488.

PMID: 39386965 PMC: 11462124. DOI: 10.12688/wellcomeopenres.22719.1.


A human model of Buruli ulcer: The case for controlled human infection and considerations for selecting a Mycobacterium ulcerans challenge strain.

Muhi S, Osowicki J, OBrien D, Johnson P, Pidot S, Doerflinger M PLoS Negl Trop Dis. 2023; 17(6):e0011394.

PMID: 37384606 PMC: 10309606. DOI: 10.1371/journal.pntd.0011394.


Buruli ulcer: application of thermography for remote diagnosis of a neglected tropical disease.

Yotsu R, Vagamon B, Almamy D, Aka N, Yeboue L, Yao A Br J Dermatol. 2023; 189(2):236-238.

PMID: 37071786 PMC: 10986919. DOI: 10.1093/bjd/ljad120.


Wound healing: Natural history and risk factors for delay in Australian patients treated with antibiotics for Mycobacterium ulcerans disease.

OBrien D, Friedman N, McDonald A, Callan P, Hughes A, Walton A PLoS Negl Trop Dis. 2018; 12(3):e0006357.

PMID: 29554101 PMC: 5875894. DOI: 10.1371/journal.pntd.0006357.


Mycobacterium ulcerans in the Elderly: More Severe Disease and Suboptimal Outcomes.

OBrien D, Friedman N, Cowan R, Pollard J, McDonald A, Callan P PLoS Negl Trop Dis. 2015; 9(12):e0004253.

PMID: 26630648 PMC: 4667883. DOI: 10.1371/journal.pntd.0004253.

References
1.
Friedman N, McDonald A, Robson M, OBrien D . Corticosteroid use for paradoxical reactions during antibiotic treatment for Mycobacterium ulcerans. PLoS Negl Trop Dis. 2012; 6(9):e1767. PMC: 3459890. DOI: 10.1371/journal.pntd.0001767. View

2.
Friedman N, Athan E, Hughes A, Khajehnoori M, McDonald A, Callan P . Mycobacterium ulcerans disease: experience with primary oral medical therapy in an Australian cohort. PLoS Negl Trop Dis. 2013; 7(7):e2315. PMC: 3715400. DOI: 10.1371/journal.pntd.0002315. View

3.
OBrien D, Jenkin G, Buntine J, Steffen C, McDonald A, Horne S . Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update. Med J Aust. 2014; 200(5):267-70. DOI: 10.5694/mja13.11331. View

4.
Martins T, Trigo G, Fraga A, Gama J, Longatto-Filho A, Saraiva M . Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection. PLoS Negl Trop Dis. 2012; 6(11):e1925. PMC: 3510087. DOI: 10.1371/journal.pntd.0001925. View

5.
Jenkin G, Smith M, Fairley M, Johnson P . Acute, oedematous Mycobacterium ulcerans infection in a farmer from far north Queensland. Med J Aust. 2002; 176(4):180-1. DOI: 10.5694/j.1326-5377.2002.tb04350.x. View